Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics

Glycoconjugate Journal

Volumn 33, Issue 4, 2016, Pages 513-525

  Rabbani, Naila ^a   Xue, Mingzhan ^b   Thornalley, Paul J ^a,b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Cardiovascular disease; Diabetes, cancer; Glycation; Glyoxalase; Methylglyoxal; Obesity; Renal failure; Therapeutics

Indexed keywords

1,2 DICARBONYL DERIVATIVE; ALDEHYDE DEHYDROGENASE; ALDOKETO REDUCTASE; GLUCOSE TRANSPORTER 1; GLYOXALASE; GLYOXALASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXIDOREDUCTASE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ADVANCED GLYCATION END PRODUCT; GLO1 PROTEIN, HUMAN; LACTOYLGLUTATHIONE LYASE; METHYLGLYOXAL;

AGING; ANAEROBIC GLYCOLYSIS; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHEMICAL STRESS; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; ENZYME ACTIVITY; ENZYME BINDING; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; GLYCATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIVER CANCER; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VASCULAR DISEASE; ANIMAL; DYSLIPIDEMIA; METABOLISM; NEOPLASM;

AGING; ANIMALS; DYSLIPIDEMIAS; GLYCATION END PRODUCTS, ADVANCED; HUMANS; LACTOYLGLUTATHIONE LYASE; NEOPLASMS; PYRUVALDEHYDE; VASCULAR DISEASES;

EID: 84978132217     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-016-9705-z     Document Type: Article

References (140)

1. Rabbani N., Thornalley P.J.: Glyoxalase centennial conference: introduction, history of research on the glyoxalase system and future prospects. Biochem. Soc. Trans. 42(2), 413–418 (2014)
2. Rabbani N., Thornalley P.J.: Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples. Nat. Protoc. 9(8), 1969–1979 (2014)
3. Thornalley P.J., Rabbani N.: Assay of methylglyoxal and glyoxal and control of peroxidase interference Biochem. Soc. Transit. 42(2), 504–510 (2014)
4. Rabbani, N., Thornalley, P.J.: Dicarbonyls (Glyoxal, Methylglyoxal, and 3-Deoxyglucosone). In: Uremic Toxins. pp. pp. 177–192. John Wiley & Sons, Inc., (2012)
5. Ahmed N., Thornalley P.J., Dawczynski J., Franke S., Strobel J., Stein G., Haik Jr. G.M.: Methylglyoxal-derived hydroimidazolone advanced glycation endproducts of human lens proteins. Investig. Ophthalmol. Vis. Sci. 44(12), 5287–5292 (2003)
6. McLellan A.C., Thornalley P.J., Benn J., Sonksen P.H.: The glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin. Sci. 87(1), 21–29 (1994)
7. Matafome P., Sena C., Seiça R.: Methylglyoxal, obesity, and diabetes. Endocr. 43(3), 472–484 (2013). doi:10.1007/s12020-012-9795-8
8. Maessen D.E.M., Stehouwer C.D.A., Schalkwijk C.G.: The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases. Clin. Sci. 128(12), 839–861 (2015)
9. Veech R.I., Rajiman L., Dalziel K., Krebs H.A.: Disequilibrium in the triose phosphate isomerase system. Biochem. J. 115(4), 837–842 (1969)
10. Phillips S.A., Thornalley P.J.: The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur. J. Biochem. 212(1), 101–105 (1993)
11. Thornalley P.J.: Modification of the glyoxalase system in human red blood cells by glucose in vitro. Biochem.J. 254(3), 751–755 (1988)
12. Ellis K.J.: Human body composition: in vivo methods. Physiol. Rev. 80(2), 649–680 (2000)
13. Reichard G.A., Skutches C.L., Hoeldtke R.D., Owen O.E.: Acetone metabolism in humans during diabetic ketoacidosis. Diabetes. 35(6), 668–674 (1986)
14. Balasse E.O.: Kinetics of ketone body metabolism in fasting humans. Metabolism. 28(1), 41–50 (1979)
15. Magee, M.S., Knopp, R.H., Benedetti, T.J.: Metabolic effects of 1200-kcal diet in obese pregnant women with gestational diabetes. Diabetes 39(2), 234–240 (1990).
16. Lyles G.A., Chalmers J.: The metabolism of aminoacetone to methylglyoxal by semicarbazide- sensitive amino oxidase in human umbilical artery. Biochem. Pharmacol. 43(7), 1409–1414 (1992)
17. Kazachkov, M., Yu, P.H.: A novel HPLC procedure for detection and quantification of aminoacetone, a precursor of methylglyoxal, in biological samples. J. Chromatogr. B 824(1–2), 116–122 (2005).
18. Stolen C.M., Yegutkin G.G., Kurkijärvi R., Bono P., Alitalo K., Jalkanen S.: Origins of serum semicarbazide-sensitive amine oxidase. Circ. Res. 95(1), 50–57 (2004)
19. Pannecoeck, R., Serruys, D., Benmeridja, L., Delanghe, J.R.: Vascular adhesion protein-1: Role in human pathology and application as a biomarker. Crit. Rev. Clin. Lab. Sci. 52(6), 284–300 (2015).
20. Thornalley P.J., Langborg A., Minhas H.S.: Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 344(1), 109–116 (1999)
21. Thornalley P.J., Rabbani N.: Dicarbonyls in cola drinks sweetened with sucrose or high fructose corn syrup. In: Thomas M.C., Forbes J. (eds.) Maillard reaction: Interface between aging, nutrition and metabolism, pp. 158–163. RSC Publishing, London (2010)
22. Degen J., Hellwig M., Henle T.: 1,2-dicarbonyl compounds in commonly consumed foods. J. Agric. Food Chem. 60(28), 7071–7079 (2012)
23. Degen J., Vogel M., Richter D., Hellwig M., Henle T.: Metabolic transit of dietary methylglyoxal. J. Agric. Food Chem. 61(43), 10253–10260 (2013)
24. Degen J., Beyer H., Heymann B., Hellwig M., Henle T.: Dietary influence on urinary excretion of 3-deoxyglucosone and its metabolite 3-Deoxyfructose. J. Agric. Food Chem. 62(11), 2449–2456 (2014)
25. Thornalley P.J., Battah S., Ahmed N., Karachalias N., Agalou S., Babaei-Jadidi R., Dawnay A.: Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 375(3), 581–592 (2003)
26. Ahmed N., Babaei-Jadidi R., Howell S.K., Beisswenger P.J., Thornalley P.J.: Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia. 48(8), 1590–1603 (2005)
27. Larsen K., Aronsson A.C., Marmstal E., Mannervik B.: Immunological comparison of glyoxalase I from yeast and mammals with quantitative determination of the enzyme in human tissues by radioimmunoassay. Comp. Biochem. Physiol. B. 82(4), 625–638 (1985)
28. Nishimura C., Furue M., Ito T., Ohmori Y., Tanimoto T.: Quantitative determination of human aldose reductase by enzyme-linked immunosorbent assay. Biochem. Pharmacol. 46(1), 21–28 (1993)
29. Schwanhausser B., Busse D., Li N., Dittmar G., Schuchhardt J., Wolf J., Chen W., Selbach M.: Global quantification of mammalian gene expression control. Nature. 473(7347), 337–342 (2011)
30. Collard F., Vertommen D., Fortpied J., Duester G., Van Schaftingen E.: Identification of 3-deoxyglucosone dehydrogenase as aldehyde dehydrogenase 1 A1 (retinaldehyde dehydrogenase 1). Biochimie. 89(3), 369–373 (2007)
31. Rabbani N., Xue M., Thornalley P.J.: Activity, regulation, copy number and function in the glyoxalase system. Biochem. Soc. Trans. 42(2), 419–424 (2014)
32. Xue M., Rabbani N., Momiji H., Imbasi P., Anwar M.M., Kitteringham N.R., Park B.K., Souma T., Moriguchi T., Yamamoto M., Thornalley P.J.: Transcriptional control of glyoxalase 1 by Nrf2 provides a stress responsive defence against dicarbonyl glycation. Biochem. J. 443(1), 213–222 (2012)
33. Kwak M.K., Wakabayashi N., Itoh K., Motohashi H., Yamamoto M., Kensler T.W.: Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem. 278(10), 8135–8145 (2003)
34. MacLeod A.K., McMahon M., Plummer S.M., Higgins L.G., Penning T.M., Igarashi K., Hayes J.D.: Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis. 30(9), 1571–1580 (2009)
35. Nishinaka T., Yabe-Nishimura C.: Transcription factor Nrf2 regulates promoter activity of mouse aldose reductase (AKR1B3) Gene. J. Pharmacol. Sci. 97(1), 43–51 (2005)
36. Thimmulappa R.K., Mai K.H., Srisuma S., Kensler T.W., Yamamoto M., Biswal S.: Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide array. Cancer Res. 62(18), 5196–5203 (2002)
37. Zhang H., Li H., Xi H.S., Li S.: HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells. Blood. 119(11), 2595–2607 (2012)
38. Tripodis N., Mason R., Humphray S.J., Davies A.F., Herberg J.A., Trowsdale J., Nizetic D., Senger G., Ragoussis J.: Physical Map of Human 6p21.2–6p21.3: Region Flanking the Centromeric End of the Major Histocompatibility Complex. Genome Res. 8(6), 631–643 (1998)
39. Meo T., Douglas T., Rijnbeek A.M.: Glyoxalase-I polymorphism in mouse - new genetic-marker linked to H-2. Science. 198(4314), 311–313 (1977)
40. Ranganathan S., Ciaccio P.J., Walsh E.S., Tew K.D.: Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. Gene. 240(1), 149–155 (1999)
41. Gale C.P., Grant P.J.: The characterisation and functional analysis of the human glyoxalase-1 gene using methods of bioinformatics. Gene. 340(2), 251–260 (2004)
42. Redon, R., Ishikawa, S., Fitch, K.R., Feuk, L., Perry, G.H., Andrews, T.D., Fiegler, H., Shapero, M.H., Carson, A.R., Chen, W., Cho, E.K., Dallaire, S., Freeman, J.L., Gonzalez, J.R., Gratacos, M., Huang, J., Kalaitzopoulos, D., Komura, D.: Global variation in copy number in the human genome. Nature 444(7118), 444–454 (2006).
43. Williams R., Lim J.E., Harr B., Wing C., Walters R., Distler M.G., Teschke M., Wu C., Wiltshire T., Su A.I., Sokoloff G., Tarantino L.M., Borevitz J.O., Palmer A.A.: A common and unstable copy number variant is associated with differences in Glo-1 expression and anxiety-like behavior. PLoS One. 4(3), e4649 (2009)
44. Cahan P., Li Y., Izumi M., Graubert T.A.: The impact of copy number variation on local gene expression in mouse hematopoietic stem and progenitor cells. Nat. Genet. 41(4), 430–437 (2009)
45. Shafie A., Xue M.Z., Thornalley P.J., Rabbani N.: Copy number variation of glyoxalase I. Biochem. Soc. Trans. 42(2), 500–503 (2014)
46. Abordo E.A., Minhas H.S., Thornalley P.J.: Accumulation of α-oxoaldehydes during oxidative stress. A role in cytotoxicity. Biochem. Pharmacol. 58(4), 641–648 (1999)
47. Edwards L.G., Adesida A., Thornalley P.J.: Inhibition of human leukaemia 60 cell growth by S -D-lactoylglutathione in vitro. Mediation by metabolism to N -D-lactoylcysteine and induction of apoptosis. Leuk. Res. 20, 17–26 (1996)
48. Ahmed N., Dobler D., Dean M., Thornalley P.J.: Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J. Biol. Chem. 280(7), 5724–5732 (2005)
49. Rabbani N., Thornalley P.J.: Glycation research in amino acids: a place to call home. Amino Acids. 42(4), 1087–1096 (2012)
50. Rabbani N., Thornalley P.J.: Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino Acids. 42(4), 1133–1142 (2012)
51. Hoon, S., Gebbia, M., Costanzo, M., Davis, R.W., Giaever, G., Nislow, C.: A global perspective of the genetic basis for carbonyl stress resistance. G3 (Bethesda, Md.) 1(3) (2011).
52. Morcos M., Du X., Pfisterer F., Hutter H., Sayed A.A.R., Thornalley P., Ahmed N., Baynes J., Thorpe S., Kukudov G., Schlotterer A., Bozorgmehr F., El Baki R.A., Stern D., Moehrlen F., Ibrahim Y., Oikonomou D., Hamann A., Becker C., Zeier M., Schwenger V., Miftari N., Humpert P., Hammes H.P., Buechler M., Bierhaus A., Brownlee M., Nawroth P.P.: Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell. 7(2), 260–269 (2008)
53. Yao D., Brownlee M.: Hyperglycemia-induced reactive oxygen species increase expression of RAGE and RAGE ligands. Diabetes. 59(1), 249–255 (2009)
54. Chan W.H., Wu H.J., Shiao N.H.: Apoptotic signaling in methylglyoxal-treated human osteoblasts involves oxidative stress, c-Jun N-terminal kinase, caspase-3, and p21-activated kinase 2. J. Cell. Biochem. 100(4), 1056–1069 (2007)
55. Dobler D., Ahmed N., Song L.J., Eboigbodin K.E., Thornalley P.J.: Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes. 55(7), 1961–1969 (2006)
56. Nagaraj R.H., Oya-Ito T., Padayatti P.S., Kumar R., Mehta S., West K., Levison B., Sun J., Crabb J.W., Padival A.K.: Enhancement of chaperone function of alpha-crystallin by methylglyoxal modification. Biochemistry. 42(36), 10746–10755 (2003)
57. Gangadhariah M.H., Wang B.L., Linetsky M., Henning C., Spanneberg R., Glomb M.A., Nagaraj R.H.: Hydroimidazolone modification of human alpha A-crystallin: effect on the chaperone function and protein refolding ability. Biochim. Biophys. Acta. 1802(4), 432–441 (2010)
58. Schalkwijk C.G., van Bezu J., van der Schors R.C., Uchida K., Stehouwer C.D.A., van Hinsbergh V.W.M.: Heat-shock protein 27 is a major methylglyoxal-modified protein in endothelial cells. FEBS Lett. 580(6), 1565–1570 (2006)
59. Rabbani N., Thornalley P.J.: Dicarbonyl proteome and genome damage in metabolic and vascular disease. Biochem. Soc. Trans. 42(2), 425–432 (2014)
60. Oya-Ito T., Naito Y., Takagi T., Handa O., Matsui H., Yamada M., Shima K., Yoshikawa T.: Heat-shock protein 27 (Hsp27) as a target of methylglyoxal in gastrointestinal cancer. Biochim. Biophys. Acta. 1812(7), 769–781 (2011)
61. Kang Y., Edwards L.G., Thornalley P.J.: Effect of methylglyoxal on human leukaemia 60 cell growth: modification of DNA, G 1 growth arrest and induction of apoptosis. Leuk. Res. 20, 397–405 (1996)
62. Thornalley P.J., Edwards L.G., Kang Y., Wyatt C., Davies N., Ladan M.J., Double J.: Antitumour activity of S-p- bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. Biochem. Pharmacol. 51(10), 1365–1372 (1996)
63. Thornalley P.J., Waris S., Fleming T., Santarius T., Larkin S.J., Winklhofer-Roob B.M., Stratton M.R., Rabbani N.: Imidazopurinones are markers of physiological genomic damage linked to DNA instability and glyoxalase 1-associated tumour multidrug resistance. Nucleic Acids Res. 38(16), 5432–5442 (2010)
64. Rabbani N., Godfrey L., Xue M., Shaheen F., Geoffrion M., Milne R., Thornalley P.J.: Conversion of low density lipoprotein to the pro-atherogenic form by methylglyoxal with increased arterial proteoglycan binding and aortal retention. Diabetes. 60(7), 1973–1980 (2011)
65. Thornalley P.J.: Dicarbonyl intermediates in the Maillard reaction. Ann. N. Y. Acad. Sci. 1043, 111–117 (2005)
66. Winterbourn C.C.: Reconciling the chemistry and biology of reactive oxygen species. Nat. Chem. Biol. 4(5), 278–286 (2008)
67. Ikeda Y., Inagi R., Miyata T., Nagai R., Arai M., Miyashita M., Itokawa M., Fujita T., Nangaku M.: Glyoxalase I retards renal senescence. Amer. J. Pathol. 179(6), 2810–2821 (2011)
68. Fan X., Sell D.R., Zhang J., Nemet I., Theves M., Lu J., Strauch C., Halushka M.K., Monnier V.M.: Anaerobic vs aerobic pathways of carbonyl and oxidant stress in human lens and skin during aging and in diabetes: a comparative analysis. Free Radic. Biol. Med. 49(5), 847–856 (2010)
69. Fleming T.H., Theilen T.M., Masania J., Wunderle M., Karimi J., Vittas S., Bernauer R., Bierhaus A., Rabbani N., Thornalley P.J., Kroll J., Tyedmers J., Nawrotzki R., Herzig S., Brownlee M., Nawroth P.P.: Aging-dependent reduction in glyoxalase 1 delays wound healing. Gerontology. 59(5), 427–437 (2013)
70. Ahmed E.K., Rogowska-Wrzesinska A., Roepstorff P., Bulteau A.L., Friguet B.: Protein modification and replicative senescence of WI-38 human embryonic fibroblasts. Aging Cell. 9(2), 252–272 (2010)
71. James E.L., Michalek R.D., Pitiyage G.N., de Castro A.M., Vignola K.S., Jones J., Mohney R.P., Karoly E.D., Prime S.S., Parkinson E.K.: Senescent human fibroblasts show increased glycolysis and redox homeostasis with extracellular metabolomes that overlap with those of irreparable DNA damage, aging, and disease. J. Proteome Res. 14(4), 1854–1871 (2015)
72. Bechtold U., Rabbani N., Mullineaux P.M., Thornalley P.J.: Quantitative measurement of specific biomarkers for protein oxidation, nitration and glycation in Arabidopsis leaves. Plant J. 59(4), 661–671 (2009)
73. Wuschke S., Dahm S., Schmidt C., Joost H.G., Al Hasani H.: A meta-analysis of quantitative trait loci associated with body weight and adiposity in mice. Int. J. Obes. 31(5), 829–841 (2006)
74. Wilson A.F., Elston R.C., Tran L.D., Siervogel R.M.: Use of the robust sib-pair method to screen for single-locus, multiple-locus, and pleiotropic effects: application to traits related to hypertension. Amer J Human Genet. 48(5), 862–872 (1991)
75. Sanchez J.C., Converse V., Nolan A., Schmid G., Wang S., Heller M., Sennitt M.V., Hochstrasser D.F., Cawthorne M.A.: Effect of rosiglitazone on the differential expression of diabetes-associated proteins in pancreatic islets of C57BI/6 lep/lep mice. Mol. Cell. Proteomics. 1(7), 509–516 (2002)
76. Wortmann, M., Hakimi, M., Fleming, T., Peters, A., Nawroth, P., Bockler, D., Dihlmann, S.: The role of glyoxalase-1 (Glo-1) in mouse metabolism and atherosclerosis. Biochem.Soc.Trans., www.biochemistry.org/Portals/0/Conferences/abstracts/SA158/SA158P005.pdf (2013).
77. Maessen, D., Brouwers, O., Miyata, T., Stehouwer, C., Schalkwijk, C.: Glyoxalase-1 overexpression reduces body weight and adipokine expression, and improves insulin sensitivity in high-fat diet-induced obese mice. Diabetologia 57, Supplement 1, 713 (2014).
78. Li S.Y., Liu Y., Sigmon V.K., McCort A., Ren J.: High-fat diet enhances visceral advanced glycation end products, nuclear O-Glc-Nac modification, p38 mitogen-activated protein kinase activation and apoptosis. Diabetes Obesity & Metabolism. 7(4), 448–454 (2005)
79. Bierhaus A., Fleming T., Stoyanov S., Leffler A., Babes A., Neacsu C., Sauer S.K., Eberhardt M., Schnolzer M., Lasischka F., Neuhuber W.L., Kichko T.I., Konrade I., Elvert R., Mier W., Pirags V., Lukic I.K., Morcos M., Dehmer T., Rabbani N., Thornalley P.J., Edelstein D., Nau C., Forbes J., Humpert P.M., Schwaninger M., Ziegler D., Stern D.M., Cooper M.E., Haberkorn U., Brownlee M., Reeh P.W., Nawroth P.P.: Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat. Med. 18(6), 926–933 (2012)
80. Barati M.T., Merchant M.L., Kain A.B., Jevans A.W., McLeish K.R., Klein J.B.: Proteomic analysis defines altered cellular redox pathways and advanced glycation end-product metabolism in glomeruli of db/db diabetic mice. Amer J Physiol - Renal Physiology. 293(4), F1157–F1165 (2007)
81. Palsamy P., Subramanian S.: Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2/Keap1 signaling. Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1812(7), 719–731 (2011)
82. Miller A.G., Tan G., Binger K.J., Pickering R.J., Thomas M.C., Nagaraj R.H., Cooper M.E., Wilkinson-Berka J.L.: Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase 1 function. Diabetes. 59(12), 3208–3215 (2010)
83. Karachalias N., Babaei-Jadidi R., Rabbani N., Thornalley P.J.: Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia. 53(7), 1506–1516 (2010)
84. Giacco F., Du X., D’Agati V.D., Milne R., Sui G., Geoffrion M., Brownlee M.: Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes. 63(1), 291–299 (2014)
85. Berner A.K., Brouwers O., Pringle R., Klaassen I., Colhoun L., McVicar C., Brockbank S., Curry J.W., Miyata T., Brownlee M., Schlingemann R.O., Schalkwijk C., Stitt A.W.: Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia. 55(3), 845–854 (2012)
86. Babaei-Jadidi R., Karachalias N., Ahmed N., Battah S., Thornalley P.J.: Prevention of incipient diabetic nephropathy by high dose thiamine and benfotiamine. Diabetes. 52(8), 2110–2120 (2003)
87. Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., Lin J., Bierhaus A., Nawroth P., Hannak D., Neumaier M., Bergfeld R., Giardino I., Brownlee M.: Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 9(3), 294–299 (2003)
88. Shinohara M., Thornalley P.J., Giardino I., Beisswenger P.J., Thorpe S.R., Onorato J., Brownlee M.: Overexpression of glyoxalase I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycaemia-induced increases in macromolecular endocytosis. J. Clin. Invest. 101(5), 1142–1147 (1998)
89. Geoffrion M., Du X., Irshad Z., Vanderhyden B.C., Courville K., Sui G., D'Agati V.D., Ott-Braschi S., Rabbani N., Thornalley P.J., Brownlee M., Milne R.W.: Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice. Phys. Rep. 2(6), e12043 (2014)
90. Pun P.B.L., Logan A., Darley-Usmar V., Chacko B., Johnson M.S., Huang G.W., Rogatti S., Prime T.A., Methner C., Krieg T., Fearnley I.M., Larsen L., Larsen D.S., Menger K.E., Collins Y., James A.M., Kumar G.D.K., Hartley R.C., Smith R.A.J., Murphy M.P.: A mitochondria-targeted mass spectrometry probe to detect glyoxals: implications for diabetes. Free Radic. Biol. Med. 67, 437–450 (2014)
91. Duran-Jimenez B., Dobler D., Moffatt S., Rabbani N., Streuli C.H., Thornalley P.J., Tomlinson D.R., Gardiner N.J.: Advanced glycation endproducts in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes. 58, 2893–2903 (2009)
92. Phillips S.A., Mirrlees D., Thornalley P.J.: Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil. Biochem.Pharmacol. 46, 805–811 (1993)
93. Genuth S., Sun W., Cleary P., Gao X., Sell D.R., Lachin J.: Skin Advanced Glycation Endproducts (AGEs) Glucosepane and Methylglyoxal Hydroimidazolone are Independently Associated with Long-term Microvascular Complication Progression of Type I diabetes. Diabetes. 64(1), 266–278 (2015)
94. Hanssen N.M.J., Beulens J.W.J., van Dieren S., Scheijen J.L.J.M., van der A D.L., Spijkerman A.M.W., van der Schouw Y.T., Stehouwer C.D.A., Schalkwijk C.G.: Plasma Advanced Glycation End Products Are Associated With Incident Cardiovascular Events in Individuals With Type 2 Diabetes: A Case-Cohort Study With a Median Follow-up of 10 Years (EPIC-NL). Diabetes. 64(1), 257–265 (2015)
95. Perkins B.A., Rabbani N., Weston A., Ficociello L.H., Adaikalakoteswari A., Niewczas M., Warram J., Krolewski A.S., Thornalley P.: Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes. PLoS One. 7(4), e35655 (2012)
96. Nigro C., Raciti G., Leone A., Fleming T., Longo M., Prevenzano I., Fiory F., Mirra P., D’Esposito V., Ulianich L., Nawroth P., Formisano P., Beguinot F., Miele C.: Methylglyoxal impairs endothelial insulin sensitivity both in vitro and in vivo. Diabetologia. 57(7), 1485–1494 (2014)
97. Kim M.J., Kim D.W., Lee B.R., Shin M.J., Kim Y.N., Eom S.A., Park B.J., Cho Y.S., Han K.H., Park J., Hwang H.S., Eum W.S., Choi S.Y.: Transduced tat-glyoxalase protein attenuates streptozotocin-induced diabetes in a mouse model. Biochem. Biophys. Res. Commun. 430(1), 294–300 (2013)
98. Maessen D.E., Hanssen N.M., Scheijen J.L., van der Kallen C.J., van Greevenbroek M.M., Stehouwer C.D., Schalkwijk C.G.: Post–glucose load plasma α-dicarbonyl concentrations are increased in individuals with impaired glucose metabolism and type 2 diabetes: the CODAM study. Diabetes Care. 38(5), 913–920 (2015)
99. Rabbani N., Sebekova K., Sebekova Jr. K., Heidland A., Thornalley P.J.: Protein glycation, oxidation and nitration free adduct accumulation after bilateral nephrectomy and ureteral ligation. Kidney Int. 72(9), 1113–1121 (2007)
100. Agalou S., Ahmed N., Babaei-Jadidi R., Dawnay A., Thornalley P.J.: Profound mishandling of protein glycation degradation products in uremia and dialysis. J. Amer. Soc. Nephrol. 16(5), 1471–1485 (2005)
101. Nangaku M.: Chronic hypoxia and Tubulointerstitial injury: a final common pathway to end-stage renal failure. J. Amer. Soc. Nephrol. 17(1), 17–25 (2006)
102. Reiniger N., Lau K., McCalla D., Eby B., Cheng B., Lu Y., Qu W., Quadri N., Ananthakrishnan R., Furmansky M., Rosario R., Song F., Rai V., Weinberg A., Friedman R., Ramasamy R., D'Agati V., Schmidt A.M.: Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes. 59(8), 2043–2054 (2010)
103. Robin E.D., Murphy B.J., Theodore J.: Coordinate regulation of glycolysis by hypoxia in mammalian cells. J. Cell. Physiol. 118(3), 287–290 (1984)
104. Pietrzak I., Baczyk K.: Erythrocyte transketolase activity and guandino compounds in hemodialysis patients. Kidney Int. 59(S78), S97–S101 (2001)
105. Miyata T., van Ypersele de Strihou C., Imasawa T., Yoshino A., Ueda Y., Ogura H., Kominami K., Onogi H., Inagi R., Nangaku M., Kurokawa K.: Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. Kidney Int. 60(6), 2351–2359 (2001)
106. Rabbani N., Thornalley P.J.: Glyoxalase in diabetes, obesity and related disorders. Semin. Cell Dev. Biol. 22(3), 309–317 (2011)
107. Mäkinen, V.-P., Civelek, M., Meng, Q., Zhang, B., Zhu, J., Levian, C., Huan, T., Segrè, A.V., Ghosh, S., Vivar, J., Nikpay, M., Stewart, A.F.R., Nelson, C.P., Willenborg, C., Erdmann, J., Blakenberg, S., O'Donnell, C.J., März, W., Laaksonen, R., Epstein, S.E., Kathiresan, S., Shah, S.H., Hazen, S.L., Reilly, M.P., Lusis, A.J., Samani, N.J., Schunkert, H., Quertermous, T., McPherson, R., Yang, X., Assimes, T.L., the Coronary, A.D.G.-W.R., Meta-Analysis, C.: Integrative Genomics Reveals Novel Molecular Pathways and Gene Networks for Coronary Artery Disease. PLoS Genet. 10(7), e1004502 (2014).
108. Tikellis C., Pickering R.J., Tsorotes D., Huet O., Cooper M.E., Jandeleit-Dahm K., Thomas M.C.: Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes. Diabetes. 63(11), 3915–3925 (2014)
109. Nin J.W., Jorsal A., Ferreira I., Schalkwijk C.G., Prins M.H., Parving H.H., Tarnow L., Rossing P., Stehouwer C.D.: Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes a 12-year follow-up study. Diabetes Care. 34(2), 442–447 (2011)
110. Hanssen N.M.J., Wouters K., Huijberts M.S., Gijbels M.J., Sluimer J.C., Scheijen J.L.J.M., Heeneman S., Biessen E.A.L., Daemen M.J.A.P., Brownlee M., de Kleijn D.P., Stehouwer C.D.A., Pasterkamp G., Schalkwijk C.G.: Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur. Heart J. 35(17), 1137–1146 (2014)
111. Hanssen N.M.J., Brouwers O., Gijbels M.J., Wouters K., Wijnands E., Cleutjens J.P.M., De Mey J.G., Miyata T., Biessen E.A., Stehouwer C.D.A., Schalkwijk C.G.: Glyoxalase 1 overexpression does not affect atherosclerotic lesion size and severity in ApoE−/− mice with or without diabetes. Cardiovasc. Res. 104(1), 160–170 (2014)
112. Inagi R., Miyata T., Ueda Y., Yoshino A., Nangaku M., de Strihou C.V., Kurokawa K.: Efficient in vitro lowering of carbonyl stress by the glyoxalase system in conventional glucose peritoneal dialysis fluid. Kidney Int. 62(2), 679–687 (2002)
113. Godfrey L., Yamada-Fowler N., Smith J.A., Thornalley P.J., Rabbani N.: Arginine-directed glycation and decreased HDL plasma concentration and functionality. Nutrition and diabetes. 4, e134 (2014)
114. Zender L., Xue W., Zuber J., Semighini C.P., Krasnitz A., Ma B., Zender P., Kubicka S., Luk J.M., Schirmacher P., Richard McCombie W., Wigler M., Hicks J., Hannon G.J., Powers S., Lowe S.W.: An Oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell. 135(5), 852–864 (2008)
115. Sakamoto H., Mashima T., Kazaki A., Dan S., Hashimoto Y., Naito M., Tsuruo T.: Glyoxalase I is involved in resistance of human leukemia cells to antitumour agent-induced apoptosis. Blood. 95(10), 3214–3218 (2000)
116. Santarius T., Bignell G.R., Greenan C.D., Widaa S., Chen L., Mahoney C.L., Butler A., Edkins S., Waris S., Thornalley P.J., Futreal P.A., Stratton M.R.: GLO1 - a novel amplified gene in human cancer. Genes Chromosom. Cancer. 49(8), 711–725 (2010)
117. Shibata T., Ohta T., Tong K.I., Kokubu A., Odogawa R., Tsuta K., Asamura H., Yamamoto M., Hirohashi S.: Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. U. S. A. 105(36), 13568–13573 (2008)
118. Sakamoto H., Mashima T., Sato S., Hashimoto Y., Yamori T., Tsuruo T.: Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin. Cancer Res. 7(8), 2513–2518 (2001)
119. Hovatta I., Tennant R.S., Helton R., Marr R.A., Singer O., Redwine J.M., Ellison J.A., Schadt E.E., Verma I.M., Lockhart D.J., Barlow C.: Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature. 438(7068), 662–666 (2005)
120. Kromer S.A., Kessler M.S., Milfay D., Birg I.N., Bunck M., Czibere L., Panhuysen M., Putz B., Deussing J.M., Holsboer F., Landgraf R., Turck C.W.: Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J. Neurosci. 25(17), 4375–4384 (2005)
121. Distler M.G., Plant L.D., Sokoloff G., Hawk A.J., Aneas I., Wuenschell G.E., Termini J., Meredith S.C., Nobrega M.A., Palmer A.A.: Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal. J. Clin. Invest. 122(6), 2306–2315 (2012)
122. Kurz A., Rabbani N., Walter M., Bonin M., Thornalley P.J., Auburger G., Gispert S.: Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cell. Mol. Life Sci. 68(4), 721–733 (2011)
123. Conroy, P.J.: Carcinostatic activity of methylglyoxal and related substances in tumour-bearing mice. In: Submolecular Biology and Cancer: Ciba Foundation Symposium, vol. 67. pp. 271–298. Excerpta Medica, Amsterdam (1979)
124. Arai M., Yuzawa H., Nohara I., Ohnishi T., Obata N., Iwayama Y., Haga S., Toyota T., Ujike H., Arai M., Ichikawa T., Nishida A., Tanaka Y., Furukawa A., Aikawa Y., Kuroda O., Niizato K., Izawa R., Nakamura K., Mori N., Matsuzawa D., Hashimoto K., Iyo M., Sora I., Matsushita M., Okazaki Y., Yoshikawa T., Miyata T., Itokawa M.: Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch. Gen. Psychiatry. 67(6), 589–597 (2010)
125. Ahmed N., Ahmed U., Thornalley P.J., Hager K., Fleischer G.A., Munch G.: Protein glycation, oxidation and nitration marker residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J. Neurochem. 92(2), 255–263 (2004)
126. Ferguson G.P., Vanpatten S., Bucala R., Al Abed Y.: Detoxification of methylglyoxal by the nucleophilic bidentate, phenylacylthiazolium bromide. Chem. Res. Toxicol. 12(7), 617–622 (1999)
127. Thornalley P.J., Minhas H.S.: Rapid hydrolysis and slow alpha,beta-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. Biochem. Pharmacol. 57(3), 303–307 (1999)
128. Ruggiero-Lopez D., Lecomte M., Moinet G., Pattereau G., Legrarde M., Wiernsperger N.: Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem. Pharmacol. 58(11), 1765–1773 (1999)
129. Kinsky O.R., Hargraves T.L., Anumol T., Jacobsen N.E., Dai J., Snyder S.A., Monks T.J., Lau S.S.: Metformin scavenges methylglyoxal to form a novel Imidazolinone metabolite in humans. Chem. Res. Toxicol. (2016). doi:10.1021/acs.chemrestox.5b00497
130. Battah S., Ahmed N., Thornalley P.J.: Kinetics and mechanism of the reaction of metformin with methylglyoxal. Int. Congr. Ser. 1245, 355–356 (2002)
131. Adrover M., Vilanova B., Frau J., Muñoz F., Donoso J.: A comparative study of the chemical reactivity of pyridoxamine, Ac-Phe-Lys and Ac-Cys with various glycating carbonyl compounds. Amino Acids. 36(3), 437–448 (2009)
132. Alaei Shahmiri F., Soares M.J., Zhao Y., Sherriff J.: High-dose thiamine supplementation improves glucose tolerance in hyperglycemic individuals: a randomized, double-blind cross-over trial. Eur. J. Nutr. 52(7), 1821–1824 (2013)
133. Rabbani N., Shahzad Alam S., Riaz S., Larkin J.R., Akhtar M.W., Shafi T., Thornalley P.J.: High dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a pilot randomised, double-blind, placebo-controlled study. Diabetologia. 52(2), 208–212 (2009)
134. Xue, M., Momiji, H., Rabbani, N., Barker, G., Bretschneider, T., Shmygol, A., Rand, D.A., Thornalley, P.J.: Frequency modulated translocational oscillations of Nrf2 mediate the ARE cytoprotective transcriptional response Antioxidants & Redox Signaling 23(7), 613–629 (2015).
135. Xue M., Momiji H., Rabbani N., Bretschneider T., Rand D.A., Thornalley P.J.: Frequency modulated translocational oscillations of Nrf2, a transcription factor functioning like a wireless sensor. Biochem. Soc. Trans. 43(4), 669–673 (2015)
136. Malhotra D., Portales-Casamar E., Singh A., Srivastava S., Arenillas D., Happel C., Shyr C., Wakabayashi N., Kensler T.W., Wasserman W.W., Biswal S.: Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 38(17), 5718–5734 (2010)
137. Xue M., Weickert M.O., Qureshi S., Ngianga-Bakwin K., Anwar A., Waldron M., Shafie A., Messenger D., Fowler M., Jenkins G., Rabbani N., Thornalley P.J.: Improved glycemic control and vascular function in overweight and obese subjects by glyoxalase 1 inducer formulation diabetes. In: Press (2016). doi:10.2337/db2316-0153
138. Lo T.W.C., Thornalley P.J.: Inhibition of proliferation of human leukemia 60 cells by diethyl esters of glyoxalase inhibitors in vitro. Biochem. Pharmacol. 44(12), 2357–2363 (1992)
139. Thornalley P.J.: Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S -D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. Crit. Rev. in Oncol. and Haematol. 20(1–2), 99–128 (1995)
140. Sharkey E.M., O'Neill H.B., Kavarana M.J., Wang H.B., Creighton D.J., Sentz D.L., Eiseman J.L.: Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I. Cancer Chemother. Pharmacol. 46(2), 156–166 (2000)